Relmada Therapeutics Balance Sheet - Quarterly (OTCMKTS:RLMD)

Add to My Stocks
$0.95 $0 (0%) RLMD stock closing price Sep 18, 2018 (Closing)

The financial analysis of a company like Relmada Therapeutics involves checking the three financial statements of the company in detail, of which the balance sheet is one. How cash on hand has increased or decreased is one of the many indicators used while undertaking the Relmada Therapeutics stock analysis, and provides insights into the firm's financial performance. Quarterly results announcements include the release of all three financial statements, of which the balance sheet is one. Apart from analyzing Relmada Therapeutics revenue Relmada Therapeutics operating cash flow, one needs to check balance sheet items like cash, fixed assets and debt. The Relmada Therapeutics balance sheet for 2018 Q3 shows cash on hand of $4.25M. The company has a debt to equity ratio of .

View and download Relmada Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jul - Jun2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Marketable Securities----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets----------
Total Current Assets
Property Plant & Equipment----------
Accumulated Depreciation----------
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable1.09M------1.25M-1.68M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses--------1.04M1.56M
Income Taxes Payable----------
Other Current Liabilities3.95M3.68M2.51M------1.44M
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt1.57M1.27M--------
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock----------
Common Stock Net----------
Capital Surplus88.66M88.5M87.81M86.83M86.53M86.43M86.29M86.12M85.97M85.67M
Retained Earnings-90.99M-87.79M-86.36M-85.38M-83.74M-81.76M-80.73M-79.09M-75.77M-73.91M
Treasury Stock----------
Other Liabilities----------
Shareholders Equity-2.31M-1.46M1.46M2.8M4.67M5.57M7.04M10.2M11.76M
Total Liabilities & Shareholders Equity4.79M6.57M5.61M2.83M4.17M6.22M7.92M10.24M12.71M16.6M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Looking at Relmada Therapeutics historical stock prices and the current Relmada Therapeutics stock price can tell you how the stock price has moved, whereas the Relmada Therapeutics PE ratio chart shows if its shares are overpriced in comparison to peers. The important things to look for in a balance sheet are:

  • Assets: An asset is a resource that a corporation like Relmada Therapeutics owns and has monetary significance. RLMD assets decreased from $6.57M in 2018 Q2 to $4.79M in 2018 Q3. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities: The total liabilities of Relmada Therapeutics for the quarter 2018 Q3 total to $7.11M. Liabilities for a company like Relmada Therapeutics include bank loans, services which have been availed for which a settlement in the form of cash/ asset transfer needs to be done in future etc. A firm takes on such obligations to grow its business which in turn will generate future economic benefits for its business.

Relmada Therapeutics Balance Sheet - Key Ratios